The Special Diabetes Program Reauthorization Act of 2025 extends federal funding for research and treatment programs focused on Type I diabetes. The bill allocates $160 million annually for fiscal years 2026 through 2030, with funds remaining available until spent rather than expiring at the end of each fiscal year. This legislation affects diabetes researchers, patients with Type I diabetes, and the health institutions that receive these grants to develop treatments and improve care. The bill was introduced by Representatives DeGette, Bilirakis, and Ruiz and modifies the existing Special Diabetes Programs authorization under the Public Health Service Act to ensure continued support for Type I diabetes initiatives over the next five years.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.